Velocity Clinical Research Medford
- Type
- Non-covered entity
- Where
- MEDFORD, OR
- Received
- $642,511 in 169 records, 2022 to 2025 ($0 general, $642,511 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | Research payment | 141 | $74,572 |
| 2024 | Research payment | 18 | $551,870 |
| 2023 | Research payment | 9 | $15,587 |
| 2022 | Research payment | 1 | $480 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| GlaxoSmithKline, LLC. | 9 | $500,616 | 2022–2024 |
| Boehringer Ingelheim International GmbH | 122 | $80,761 | 2024–2025 |
| Amgen Inc. | 6 | $35,122 | 2024–2025 |
| PFIZER INC. | 29 | $24,102 | 2023–2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $1,908 | 2024–2025 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 169 | $642,511 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-05 | PFIZER INC. | $426 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND | 2025 | |
| 2025-12-05 | PFIZER INC. | $426 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND | 2025 | |
| 2025-12-05 | PFIZER INC. | $426 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND | 2025 | |
| 2025-12-05 | PFIZER INC. | $426 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND | 2025 | |
| 2025-12-05 | PFIZER INC. | $426 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND | 2025 | |
| 2025-12-05 | PFIZER INC. | $426 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND | 2025 | |
| 2025-12-05 | PFIZER INC. | $426 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND | 2025 | |
| 2025-12-05 | PFIZER INC. | $426 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND | 2025 | |
| 2025-12-05 | PFIZER INC. | $426 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND | 2025 | |
| 2025-12-05 | PFIZER INC. | $426 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND | 2025 | |
| 2025-12-05 | PFIZER INC. | $426 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND | 2025 | |
| 2025-12-05 | PFIZER INC. | $426 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND | 2025 | |
| 2025-12-05 | PFIZER INC. | $426 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND | 2025 | |
| 2025-12-05 | PFIZER INC. | $426 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND | 2025 | |
| 2025-12-05 | PFIZER INC. | $426 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND | 2025 | |
| 2025-12-05 | PFIZER INC. | $426 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND | 2025 | |
| 2025-12-05 | PFIZER INC. | $426 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND | 2025 | |
| 2025-12-05 | PFIZER INC. | $426 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND | 2025 | |
| 2025-12-05 | PFIZER INC. | $426 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND | 2025 | |
| 2025-12-05 | PFIZER INC. | $426 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND | 2025 | |
| 2025-12-01 | Boehringer Ingelheim International GmbH | $47 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-12-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-12-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-12-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-12-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-12-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-11-26 | Boehringer Ingelheim International GmbH | $4,355 | Research payment | Cash or cash equivalent | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 | |
| 2025-11-26 | Boehringer Ingelheim International GmbH | $650 | Research payment | Cash or cash equivalent | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 | |
| 2025-11-26 | Boehringer Ingelheim International GmbH | $130 | Research payment | Cash or cash equivalent | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 | |
| 2025-11-19 | Boehringer Ingelheim International GmbH | $109 | Research payment | In-kind items and services | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 | |
| 2025-11-19 | Boehringer Ingelheim International GmbH | $109 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-11-19 | Boehringer Ingelheim International GmbH | $5 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-11-17 | Boehringer Ingelheim International GmbH | $581 | Research payment | Cash or cash equivalent | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 | |
| 2025-11-17 | Boehringer Ingelheim International GmbH | $156 | Research payment | Cash or cash equivalent | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 | |
| 2025-11-17 | Boehringer Ingelheim International GmbH | $133 | Research payment | Cash or cash equivalent | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 | |
| 2025-11-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | $68 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-11-01 | Boehringer Ingelheim International GmbH | $47 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-11-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-11-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-11-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-11-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-11-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-10-27 | Boehringer Ingelheim International GmbH | $219 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-10-27 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-10-01 | Boehringer Ingelheim International GmbH | $47 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-10-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-10-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-10-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-10-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-10-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-09-24 | Boehringer Ingelheim International GmbH | $11 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-09-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-09-01 | Boehringer Ingelheim International GmbH | $47 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-09-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-09-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-09-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-09-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-09-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-08-28 | Boehringer Ingelheim International GmbH | $12,444 | Research payment | Cash or cash equivalent | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 | |
| 2025-08-28 | Boehringer Ingelheim International GmbH | $969 | Research payment | Cash or cash equivalent | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 | |
| 2025-08-26 | Boehringer Ingelheim International GmbH | $36 | Research payment | In-kind items and services | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 | |
| 2025-08-26 | Boehringer Ingelheim International GmbH | $19 | Research payment | In-kind items and services | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 | |
| 2025-08-01 | Boehringer Ingelheim International GmbH | $47 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-08-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-08-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-08-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-08-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-08-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-07-28 | Boehringer Ingelheim International GmbH | $401 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-07-28 | Boehringer Ingelheim International GmbH | $15 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-07-01 | Boehringer Ingelheim International GmbH | $55 | Research payment | In-kind items and services | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 | |
| 2025-07-01 | Boehringer Ingelheim International GmbH | $47 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-07-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-07-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-07-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-07-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-07-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-07-01 | Boehringer Ingelheim International GmbH | $30 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-06-24 | Boehringer Ingelheim International GmbH | $109 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-06-24 | Boehringer Ingelheim International GmbH | $5 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-06-01 | Boehringer Ingelheim International GmbH | $55 | Research payment | In-kind items and services | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 | |
| 2025-06-01 | Boehringer Ingelheim International GmbH | $47 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-06-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-06-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-06-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-06-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-06-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-05-27 | Boehringer Ingelheim International GmbH | $584 | Research payment | In-kind items and services | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 | |
| 2025-05-27 | Boehringer Ingelheim International GmbH | $174 | Research payment | In-kind items and services | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 | |
| 2025-05-27 | Boehringer Ingelheim International GmbH | $99 | Research payment | In-kind items and services | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 | |
| 2025-05-27 | Boehringer Ingelheim International GmbH | $79 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-05-27 | Boehringer Ingelheim International GmbH | $29 | Research payment | In-kind items and services | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 | |
| 2025-05-27 | Boehringer Ingelheim International GmbH | $11 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-05-27 | Boehringer Ingelheim International GmbH | $6 | Research payment | In-kind items and services | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 | |
| 2025-05-01 | Boehringer Ingelheim International GmbH | $55 | Research payment | In-kind items and services | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 | |
| 2025-05-01 | Boehringer Ingelheim International GmbH | $47 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-05-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-05-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-05-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-05-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-05-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-04-23 | Boehringer Ingelheim International GmbH | $109 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-04-23 | Boehringer Ingelheim International GmbH | $109 | Research payment | In-kind items and services | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 | |
| 2025-04-23 | Boehringer Ingelheim International GmbH | $5 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-04-01 | Boehringer Ingelheim International GmbH | $55 | Research payment | In-kind items and services | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 | |
| 2025-04-01 | Boehringer Ingelheim International GmbH | $47 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-04-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-04-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-04-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-04-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-04-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-03-01 | Boehringer Ingelheim International GmbH | $55 | Research payment | In-kind items and services | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 | |
| 2025-03-01 | Boehringer Ingelheim International GmbH | $47 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-03-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-03-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-03-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-03-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-03-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-02-25 | Boehringer Ingelheim International GmbH | $292 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-02-13 | Boehringer Ingelheim International GmbH | $14,500 | Research payment | Cash or cash equivalent | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 | |
| 2025-02-13 | Boehringer Ingelheim International GmbH | $5,000 | Research payment | Cash or cash equivalent | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 | |
| 2025-02-13 | Boehringer Ingelheim International GmbH | $1,500 | Research payment | Cash or cash equivalent | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 | |
| 2025-02-01 | Boehringer Ingelheim International GmbH | $55 | Research payment | In-kind items and services | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 | |
| 2025-02-01 | Boehringer Ingelheim International GmbH | $47 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-02-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-02-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-02-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-02-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-02-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-01-30 | Amgen Inc. | $8,972 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatin | 2025 | |
| 2025-01-27 | Amgen Inc. | $10,342 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatin | 2025 | |
| 2025-01-27 | Boehringer Ingelheim International GmbH | $0 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-01-27 | Boehringer Ingelheim International GmbH | $0 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-01-01 | Boehringer Ingelheim International GmbH | $86 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-01-01 | Boehringer Ingelheim International GmbH | $55 | Research payment | In-kind items and services | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 | |
| 2025-01-01 | Boehringer Ingelheim International GmbH | $47 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-01-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-01-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-01-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-01-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-01-01 | Boehringer Ingelheim International GmbH | $39 | Research payment | In-kind items and services | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2024-11-21 | Boehringer Ingelheim International GmbH | $21,000 | Research payment | Cash or cash equivalent | BI 456906 in NASH F4 - pivotal trial | 2024 | |
| 2024-10-17 | Boehringer Ingelheim International GmbH | $1,237 | Research payment | Cash or cash equivalent | BI 456906 in NASH F2/F3 - pivotal trial | 2024 | |
| 2024-09-25 | Boehringer Ingelheim International GmbH | $1,122 | Research payment | In-kind items and services | BI 456906 in NASH F4 - pivotal trial | 2024 | |
| 2024-09-01 | Boehringer Ingelheim International GmbH | $2,213 | Research payment | In-kind items and services | BI 456906 in NASH F2/F3 - pivotal trial | 2024 | |
| 2024-07-26 | Amgen Inc. | $9,903 | Research payment | Cash or cash equivalent | ASCEND P3 AD Extension | 2024 | |
| 2024-07-25 | PFIZER INC. | $11,500 | Research payment | In-kind items and services | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL | 2024 | |
| 2024-04-25 | Amgen Inc. | $850 | Research payment | In-kind items and services | STARLIGHT P2 LCM Asthma | 2024 | |
| 2024-04-23 | GlaxoSmithKline, LLC. | $482,992 | Research payment | Cash or cash equivalent | A PHASE 1, OPEN-LABEL, RANDOMIZED, PARALLEL GROUP, SINGLE-DOSE CLINICA | 2024 | |
| 2024-04-10 | PFIZER INC. | $205 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2024 | |
| 2024-04-03 | GlaxoSmithKline, LLC. | $3,953 | Research payment | Cash or cash equivalent | A PHASE 1, OPEN-LABEL, RANDOMIZED, PARALLEL GROUP, SINGLE-DOSE CLINICA | 2024 | |
| 2024-02-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,570 | Research payment | In-kind items and services | Obesity Long term safety in patients with CV risk | 2024 | |
| 2024-01-29 | GlaxoSmithKline, LLC. | $625 | Research payment | Cash or cash equivalent | A PHASE 1, OPEN-LABEL, RANDOMIZED, PARALLEL GROUP, SINGLE-DOSE CLINICA | 2024 | |
| 2024-01-25 | Amgen Inc. | $4,614 | Research payment | In-kind items and services | ASCEND P3 AD Extension | 2024 | |
| 2024-01-25 | Amgen Inc. | $439 | Research payment | In-kind items and services | SHUTTLE P3 AD Adult Combo TCS | 2024 | |
| 2024-01-16 | PFIZER INC. | $293 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2024 | |
| 2024-01-16 | PFIZER INC. | $18 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2024 | |
| 2024-01-11 | GlaxoSmithKline, LLC. | $530 | Research payment | Cash or cash equivalent | A PHASE 1, OPEN-LABEL, RANDOMIZED, PARALLEL GROUP, SINGLE-DOSE CLINICA | 2024 | |
| 2024-01-01 | Boehringer Ingelheim International GmbH | $8,799 | Research payment | In-kind items and services | Obesity Long term safety in patients with CV risk | 2024 | |
| 2023-12-19 | PFIZER INC. | $234 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2023 | |
| 2023-12-16 | PFIZER INC. | $15 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2023 | |
| 2023-10-23 | PFIZER INC. | $2,495 | Research payment | In-kind items and services | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF0726 | 2023 | |
| 2023-09-15 | PFIZER INC. | $403 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-08-21 | PFIZER INC. | $403 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-04-05 | GlaxoSmithKline, LLC. | $10,150 | Research payment | Cash or cash equivalent | A PHASE 1, OPEN-LABEL, RANDOMIZED, PARALLEL GROUP, SINGLE-DOSE CLINICA | 2023 | |
| 2023-02-13 | GlaxoSmithKline, LLC. | $715 | Research payment | Cash or cash equivalent | A PHASE 1, OPEN-LABEL, RANDOMIZED, PARALLEL GROUP, SINGLE-DOSE CLINICA | 2023 | |
| 2023-01-25 | GlaxoSmithKline, LLC. | $780 | Research payment | Cash or cash equivalent | A PHASE 1, OPEN-LABEL, RANDOMIZED, PARALLEL GROUP, SINGLE-DOSE CLINICA | 2023 | |
| 2023-01-13 | GlaxoSmithKline, LLC. | $390 | Research payment | Cash or cash equivalent | A PHASE 1, OPEN-LABEL, RANDOMIZED, PARALLEL GROUP, SINGLE-DOSE CLINICA | 2023 | |
| 2022-12-19 | GlaxoSmithKline, LLC. | $480 | Research payment | Cash or cash equivalent | A PHASE 1, OPEN-LABEL, RANDOMIZED, PARALLEL GROUP, SINGLE-DOSE CLINICA | 2022 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Medford, OR, county Jackson County, OR, state Oregon; placed by its city name.
| Measure | Place (city or town) Medford, OR | County Jackson County, OR | State Oregon |
|---|---|---|---|
| Population B01003 | 86,315 | 222,645 | 4,254,293 |
| Population, 2020 census P1 | 85,824 | 223,259 | 4,237,256 |
| Median age B01002 | 38.9 | 42.8 | 40.4 |
| Under 18 B01001 | 22.9% | 20.3% | 19.9% |
| 65 and over B01001 | 19.5% | 23.5% | 19.1% |
| Households B11001 | 34,813 | 92,035 | 1,718,422 |
| Foreign born B05002 | 6.5% | 5.3% | 9.8% |
| Median household income B19013 | $73,230 | $73,999 | $83,011 |
| Median family income B19113 | $85,987 | $90,393 | $102,281 |
| Per capita income B19301 | $37,002 | $40,709 | $45,612 |
| Poverty rate B17001 | 13.2% | 12.4% | 11.9% |
| Unemployment rate B23025 | 5.3% | 5.4% | 5.4% |
| Civilian labor force B23025 | 42,197 | 105,885 | 2,183,462 |
| Mean commute (minutes) B08013 | 16.6 | 19.1 | 23.0 |
| Bachelor's degree or higher B15003 | 30.1% | 31.7% | 36.8% |
| Housing units B25001 | 36,630 | 97,991 | 1,857,992 |
| Owner-occupied B25003 | 56.3% | 65.9% | 63.3% |
| Renters B25003 | 43.7% | 34.1% | 36.7% |
| Median home value B25077 | $417,100 | $430,200 | $477,600 |
| Median gross rent B25064 | $1,376 | $1,358 | $1,525 |
| White, not Hispanic B03002 | 72.1% | 76.8% | 71.4% |
| Black B03002 | 1.0% | 0.6% | 1.8% |
| Hispanic or Latino B03002 | 18.0% | 14.6% | 14.7% |
| Asian B03002 | 1.3% | 1.0% | 4.4% |
| American Indian and Alaska Native B03002 | 0.3% | 0.3% | 0.6% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Medford, OR.
Comments